Eko Health develops AI-enhanced digital stethoscopes and companion software that combine acoustic heart and lung sounds with ECG to aid detection of cardiac conditions. Founded in 2013, the company has sold its stethoscope to more than 500,000 physicians and healthcare providers and has amassed chest-sound and ECG data from millions of patients to train its algorithms. Eko has received FDA clearance for three algorithms, including an April clearance to help detect early signs of heart failure and recent clearance to detect heart murmurs. The company positions its AI to improve the consistency and accuracy of routine exams, bringing cardiology-level assessment to primary care and frontline clinicians. Eko plans to use the new funding to train algorithms to detect pulmonary conditions such as asthma and pneumonia and to expand sales of its device and software outside the U.S. Clinical validation includes a Massachusetts General Hospital study that found Eko’s AI identified more than twice as many patients with heart disease compared to primary care doctors. Eko develops smart stethoscopes and an FDA-cleared AI platform used by hundreds of thousands of healthcare professionals worldwide to detect and monitor heart and lung disease. The company collects phonocardiogram (PCG) and electrocardiogram (ECG) data with its DUO ECG + Digital Stethoscope to train machine-learning algorithms. Eko has partnered with Lifespan Health System’s Cardiovascular Institute to develop an algorithm that detects and stratifies pulmonary hypertension (PH). The goal is an easy-to-deploy, low-cost tool that enables earlier and more accurate identification of PH and improves clinical decision-making. Eko’s work aims to reduce long diagnostic delays and provide a scalable alternative to costly, invasive gold-standard tests. Eko develops digital stethoscopes with features such as noise-canceling, recording, and visualization of heart sounds alongside FDA-cleared clinical support algorithms. In 2020 the FDA granted 510(k) clearance to a suite of Eko algorithms for detecting heart murmurs and atrial fibrillation, and additional clinical results were published in The Journal of the American Heart Association in 2021. The company has launched Eko App, which integrates those algorithms to capture heart sounds and ECG data in the background and provide immediate analysis or summary reports in the exam room. Eko positions this software as a clinical decision support system to help clinicians—particularly in ambulatory and rural primary-care settings—interpret cardiac data. The company is pursuing broader screening for structural heart disease and heart failure, and an independent NHS trial with Mayo Clinic collaborators showed an algorithm could flag LVEF around 40% after 15 seconds of listening, though that algorithm has not yet received FDA clearance for clinical use. Eko plans to commercialize these capabilities and continue product development backed by recent funding. Eko develops a platform that pairs advanced sensors and clinician- and patient-facing software with AI algorithms to elevate detection and monitoring of cardiac and respiratory disease. The company reinvented the stethoscope and introduced a combined handheld digital stethoscope and electrocardiogram (ECG), and its AI analysis is FDA-cleared to help detect heart rhythm abnormalities and structural heart disease. Its FDA-cleared platform is used by tens of thousands of clinicians treating millions of patients around the world, both in-person and via telehealth. Eko has recently launched a telehealth platform and achieved product milestones including clearance of its AI suite. The company plans to expand in-clinic use of its telehealth and AI platform and to launch a home monitoring program for cardiopulmonary patients. Eko is headquartered in Oakland, California and announced new funding to accelerate growth. Eko develops advanced sensors, clinician and patient software, and AI algorithms integrated into a digital stethoscope platform for cardiac and respiratory disease detection and monitoring. The company’s cardiac AI algorithms are cleared by the U.S. Food and Drug Administration and it has launched an AI-powered telehealth platform. Its technology is used by tens of thousands of clinicians, in more than 1,000 institutions worldwide, treating millions of patients. Eko is headquartered in Oakland, California and is privately held. The company has strategic investors including ARTIS Ventures, NTT Venture Capital, DigiTx Ventures, Mayo Clinic, and Sutter Health. Ongoing clinical validation with academic partners is a stated priority to extend cardiologist-level auscultation to general practitioners.

Total raised

$169M

Funding rounds

9

Latest round

Series D

Latest activity

Jun 2024